Learn about UCSF’s response to the coronavirus outbreak, important updates on campus safety precautions, and the latest policies and guidance on our COVID-19 resource website. You can also access information from the CDC. Learn more
An increasing percentage of emergency visits and hospitalizations in the United States before the pandemic involved patients with alcohol and other substance use disorders, according to a study by UCSF researchers.
An initiative that paired paid visitors with racially diverse older adults, many of whom lived alone and struggled with taking care of their basic needs, resulted in reduced loneliness and plunging rates of depression.
Most patients on immunosuppressive drugs for chronic inflammatory conditions, like rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease, can still produce antibodies after receiving the mRNA COVID-19 vaccines, researchers at UCSF and Washington University have concluded.
Following groundbreaking work on a “speech neuroprosthesis” that enabled a paralyzed man to communicate using his brain signals, the lab team answered public questions about brain-computer interfaces and the limitations of translating brain signals into code.
We spoke to UCSF virologist Nadia Roan, PhD, about the latest developments in our knowledge of the Delta variant, including how the new variant spreads so efficiently, whether it causes more serious illness, and why she thinks vaccines will hold the line.
UCSF researchers have leveraged two new molecules, one of which is currently in clinical oncology trials, to devise a dual-drug therapy for alcohol use disorder (AUD), without the side effects or complications associated with current treatment regimens.
UCSF and The Atlantic have announced that the crowdsourced digital archive documenting the face of the pandemic in the United States will become part of the University’s permanent library collection and is accessible to researchers and the public.
UCSF researchers in collaboration with the Centers for Disease Control’s Tuberculosis Trials Consortium and the AIDS Clinical Trials Group published a landmark study that demonstrated a new four-month treatment regimen for tuberculosis was safe and as efficacious as the standard six-month therapy.
A UCSF study has found that the antibiotic azithromycin was no more effective than a placebo in preventing symptoms of COVID-19 among non-hospitalized patients, and may increase their chance of hospitalization, despite widespread prescription of the antibiotic for the disease.
Researchers at UC San Francisco have successfully developed a “speech neuroprosthesis” that has enabled a man with severe paralysis to communicate in sentences, translating signals from his brain to the vocal tract directly into words that appear as text on a screen.
Children with a devastating genetic disorder characterized by severe motor disability and developmental delay have experienced sometimes dramatic improvements in a gene therapy trial launched at UCSF Benioff Children’s Hospitals.